CMS Issues Coverage Guidance on GLP-1 Anti-Obesity Drugs: Implications for Health Plans Posted on April 5, 2024 CMS Issued Coverage Guidance on GLP-1 Anti-Obesity Drugs Requiring Considerations for Health Plans GLP-1s (glucagon-like peptide 1 agonist) came up in the news again after the Centers for Medicare and Medicaid Services (CMS) issued coverage guidance on GLP-1 anti-obesity drugs with expanded indications on March 20, 2024.* Since the inception of Medicare Part D, drugs used for weight loss have been excluded from basic coverage
Step 2 - Clinician Review
In rodents, non-shivering thermogenesis is mediated by the uncoupling protein-1 (UCP-1) in brown adipose tissue (51)
How will we monitor my response to treatment, and how often will I need follow-up appointments
"Although the absolute risk is low, awareness of this potential effect may help to inform treatment decisions," write the researchers
It accesses doses lower than the usual starter doses on our other GLP-1 programs, as well as additional doses up to 25% of the standard maintenance dose
/assets/images/provider/photos/2775905.jpeg)
